The Apex Times
Above the Noise
Business Wire
BusinessLockheed Martin pursues U.S. mineral supply deals tied to broader defense supply-chain push, sources sayThe Apex TimesBusinessPalantir shares rise after clearing the 200-day moving average, a chart milestone that traders watch closelyThe Apex TimesBusinessApple says memory supply constraints are likely to keep tightening, pointing to limits on advanced-chip productionThe Apex TimesBusinessMarket sentiment firms as investors watch after-hours results, with AMD in focus alongside SpaceX and Booking.comThe Apex TimesBusinessYahoo Finance highlights Wall Street’s upbeat read on Coca-Cola using an average brokerage recommendation metricThe Apex TimesBusinessUber’s Q2 update spotlights the metrics investors will watch nextThe Apex TimesBusinessDisney’s latest quarter shows how results stacked up against Wall Street expectations, with several key metrics in focusThe Apex TimesBusinessUber retreats after outlook outlines caution, even as earnings and bookings top viewsThe Apex TimesBusinessAMD slides 6% after record quarter as NVIDIA rises on SpaceX-related deal chatterThe Apex TimesBusinessTim Cook warns memory prices should keep rising, indicating a changing cost backdrop for AppleThe Apex TimesBusinessPalantir shares jump after earnings as a veteran analyst outlines renewed optimismThe Apex TimesBusinessSpotify shares fall after investor focus shifts from subscriber milestone to earnings and spendingThe Apex TimesBusinessLockheed Martin pursues U.S. mineral supply deals tied to broader defense supply-chain push, sources sayThe Apex TimesBusinessPalantir shares rise after clearing the 200-day moving average, a chart milestone that traders watch closelyThe Apex TimesBusinessApple says memory supply constraints are likely to keep tightening, pointing to limits on advanced-chip productionThe Apex TimesBusinessMarket sentiment firms as investors watch after-hours results, with AMD in focus alongside SpaceX and Booking.comThe Apex TimesBusinessYahoo Finance highlights Wall Street’s upbeat read on Coca-Cola using an average brokerage recommendation metricThe Apex TimesBusinessUber’s Q2 update spotlights the metrics investors will watch nextThe Apex TimesBusinessDisney’s latest quarter shows how results stacked up against Wall Street expectations, with several key metrics in focusThe Apex TimesBusinessUber retreats after outlook outlines caution, even as earnings and bookings top viewsThe Apex TimesBusinessAMD slides 6% after record quarter as NVIDIA rises on SpaceX-related deal chatterThe Apex TimesBusinessTim Cook warns memory prices should keep rising, indicating a changing cost backdrop for AppleThe Apex TimesBusinessPalantir shares jump after earnings as a veteran analyst outlines renewed optimismThe Apex TimesBusinessSpotify shares fall after investor focus shifts from subscriber milestone to earnings and spendingThe Apex TimesBusinessLockheed Martin pursues U.S. mineral supply deals tied to broader defense supply-chain push, sources sayThe Apex TimesBusinessPalantir shares rise after clearing the 200-day moving average, a chart milestone that traders watch closelyThe Apex TimesBusinessApple says memory supply constraints are likely to keep tightening, pointing to limits on advanced-chip productionThe Apex TimesBusinessMarket sentiment firms as investors watch after-hours results, with AMD in focus alongside SpaceX and Booking.comThe Apex TimesBusinessYahoo Finance highlights Wall Street’s upbeat read on Coca-Cola using an average brokerage recommendation metricThe Apex TimesBusinessUber’s Q2 update spotlights the metrics investors will watch nextThe Apex TimesBusinessDisney’s latest quarter shows how results stacked up against Wall Street expectations, with several key metrics in focusThe Apex TimesBusinessUber retreats after outlook outlines caution, even as earnings and bookings top viewsThe Apex TimesBusinessAMD slides 6% after record quarter as NVIDIA rises on SpaceX-related deal chatterThe Apex TimesBusinessTim Cook warns memory prices should keep rising, indicating a changing cost backdrop for AppleThe Apex TimesBusinessPalantir shares jump after earnings as a veteran analyst outlines renewed optimismThe Apex TimesBusinessSpotify shares fall after investor focus shifts from subscriber milestone to earnings and spendingThe Apex TimesBusinessLockheed Martin pursues U.S. mineral supply deals tied to broader defense supply-chain push, sources sayThe Apex TimesBusinessPalantir shares rise after clearing the 200-day moving average, a chart milestone that traders watch closelyThe Apex TimesBusinessApple says memory supply constraints are likely to keep tightening, pointing to limits on advanced-chip productionThe Apex TimesBusinessMarket sentiment firms as investors watch after-hours results, with AMD in focus alongside SpaceX and Booking.comThe Apex TimesBusinessYahoo Finance highlights Wall Street’s upbeat read on Coca-Cola using an average brokerage recommendation metricThe Apex TimesBusinessUber’s Q2 update spotlights the metrics investors will watch nextThe Apex TimesBusinessDisney’s latest quarter shows how results stacked up against Wall Street expectations, with several key metrics in focusThe Apex TimesBusinessUber retreats after outlook outlines caution, even as earnings and bookings top viewsThe Apex TimesBusinessAMD slides 6% after record quarter as NVIDIA rises on SpaceX-related deal chatterThe Apex TimesBusinessTim Cook warns memory prices should keep rising, indicating a changing cost backdrop for AppleThe Apex TimesBusinessPalantir shares jump after earnings as a veteran analyst outlines renewed optimismThe Apex TimesBusinessSpotify shares fall after investor focus shifts from subscriber milestone to earnings and spendingThe Apex Times
Back to front
Eli Lilly says Mounjaro and Zepbound are boosting sales momentum, with overall revenue accelerating
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 5, 9:46 AM EDT

Eli Lilly says Mounjaro and Zepbound are boosting sales momentum, with overall revenue accelerating

In comments reported by Yahoo Finance, Eli Lilly said its obesity treatments Mounjaro and Zepbound are driving an acceleration of its overall sales, with Mounjaro sales said to have doubled this year.

2 min readEditor-approved Apex article

Eli Lilly is pointing to its obesity franchise as a key engine of near-term growth, saying its diabetes and weight-loss medicines Mounjaro and Zepbound are pushing its overall sales higher.

According to the report, the company said Mounjaro sales have doubled this year and that the combined obesity portfolio is helping drive an acceleration in total revenue. The statement, as described in the market coverage, links the momentum to demand for both products rather than to a single one-off factor.

Mounjaro is Lilly’s brand for tirzepatide, a medicine approved for type 2 diabetes. Zepbound is Lilly’s tirzepatide brand for chronic weight management. While both use the same underlying drug ingredient, they are marketed and prescribed for different indications, and together they form the core of Lilly’s obesity strategy.

Lilly’s comments arrive as the market continues to grapple with the rapid expansion of GLP-1 and related therapies, which have reshaped demand across endocrinology and weight-management care. For Lilly, the practical question is less about whether obesity drugs are working, and more about how quickly patients can access treatment and how sustainably the company can supply and convert that demand into recurring sales.

The reported update suggests that Lilly views its obesity business as transitioning from early growth to a more durable revenue driver. By tying overall sales acceleration to Mounjaro and Zepbound, the company is effectively underscoring that the obesity portfolio is not just contributing, but increasingly dominating the trajectory of its topline performance.

The company did not provide additional detail in the brief market account, including whether the acceleration reflects changes in pricing, changes in market access, geography, manufacturing output, or a mix shift between Mounjaro and Zepbound. It also was not reported how much of the year’s doubling claim is attributable to volume versus higher realized net pricing.

In addition, the report does not include guidance changes, segment breakdowns, or a timeline for when the company expects the sales momentum to normalize, if it ever does. For investors and analysts, that means the primary takeaway is directional, not a complete forecast of quarterly results.

What to watch next is whether Lilly quantifies the drivers of growth in future filings and earnings commentary, including new demand trends for Zepbound and the extent to which Mounjaro’s diabetes patient base is translating into additional obesity-related prescriptions across payers and clinicians. Given how central the obesity franchise is to the company’s narrative, further updates on supply, demand, and product mix will likely matter as much as any headline sales growth figure.

Why It Matters

  • If sustained, faster growth tied to obesity drugs could reinforce Lilly’s position as a leading supplier in the expanding weight-management market.
  • Because Mounjaro and Zepbound share the same drug ingredient but are used for different indications, further clarity on mix and demand could help explain how durable growth may be.
  • The reported comments suggest management views the obesity portfolio as increasingly central to topline performance, which can influence how investors model Lilly’s next earnings cycles.
  • Without disclosed drivers such as pricing, volume, or supply constraints, the figures remain directional and will likely be validated in subsequent financial reporting.

Sources

Key Facts

  • Eli Lilly said its obesity treatments Mounjaro and Zepbound are driving an acceleration of overall sales, according to a Yahoo Finance report.
  • The report states that Mounjaro sales have doubled this year.
  • The obesity franchise highlighted by Lilly consists of Mounjaro (tirzepatide for type 2 diabetes) and Zepbound (tirzepatide for chronic weight management).
  • The market coverage does not include detailed numeric revenue totals, quarterly breakdowns, or guidance changes tied to the acceleration claim.

Healthcare Related

Aug 5, 10:00 AM EDT
The Apex Times

Eli Lilly’s weight-loss lineup keeps pulling the results, again

Investors are watching Eli Lilly’s demand momentum for Zepbound and Mounjaro as the company’s latest reporting reinforced a strong earnings performance and a higher sales outlook, according to a Yahoo Finance report.

Eli Lilly’s weight-loss lineup keeps pulling the results, again
The Apex Times
Eli Lilly says Mounjaro and Zepbound are boosting sales momentum, with overall revenue accelerating | The Apex Times